What Is the Mounjaro Slimming Injection and How Does It Work?

What does the Mounjaro slimming injection actually do in the body?

When you inject tirzepatide once a week, it mimics two hormones your gut normally releases after a meal: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both signals travel to the brain's appetite centres and to the stomach. The combined effect is a reduction in hunger, an increase in the sensation of fullness, and a slowing of how fast food leaves the stomach. You eat less because your body is genuinely signalling that it does not need more, not because you are forcing willpower.

That dual mechanism is what separates Mounjaro from semaglutide-based slimming pens, which act on GLP-1 alone. The practical implication is visible in the trial data: SURMOUNT-1 (2,539 adults, 72 weeks) recorded average weight reductions of around 20–21% at 15 mg. For context on how this compares to other licensed options, the weight-loss treatments overview covers the landscape. The NHS medicines page for tirzepatide also explains the mechanism in plain language if you want a second source.

If you want a closer look at how the treatment is administered, our Mounjaro injection page walks through what the process involves, from the pen itself to what to expect on your first dose. Its action is hormonal and, for most people, the reduced appetite feels natural rather than forced, a distinction patients often remark on.

How is the slimming injection given, and does the injection site matter?

Mounjaro is injected under the skin (subcutaneously) once a week, using the pre-filled KwikPen. You press the pen against the skin, press the button, and hold it for a few seconds until the dose is delivered. The pen clicks and a window confirms the injection is complete. Most people manage this straightforwardly after their first attempt.

Where you inject does matter. The three approved sites are the abdomen, the front of the thigh, and the upper arm. Rotating between sites reduces the small risk of lumps or skin changes building up in one spot. Injecting into the same patch of skin repeatedly can affect how reliably the medicine is absorbed. More detail on technique and rotation is available on our injection site guidance page.

A fresh needle should be used for every injection, reusing them increases discomfort and contamination risk. If you are setting up a routine, doing it the same day each week helps; plenty of people pick Sunday evening, or just after the 12 pm cut-off on a Monday so they can order their next pen in time for next-day delivery. Keep the pen in the fridge until you are ready. For specifics on storage windows and what to do if a pen has been out of the fridge, the Mounjaro storage page has the detail, always cross-check against your Patient Information Leaflet.

Who is the Mounjaro slimming pen licensed for in the UK, and what does the clinical assessment cover?

The UK licence covers adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone is not the whole picture, a prescriber also reviews your medical history, any current medicines, and whether any contraindications apply.

Some situations mean Mounjaro is not suitable: pregnancy, breastfeeding, or actively trying to conceive; age under 18; and certain conditions including a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Women using oral contraceptives should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption. This is covered in NHS England's guidance on weight-management injections.

On the NHS, tirzepatide is being rolled out in phases under NICE guidance (TA1026), with strict eligibility criteria. Private prescribing through a regulated pharmacy is an alternative route for people who do not meet current NHS thresholds or prefer not to wait. You can read more about the full Mounjaro injections process and what a clinical assessment involves.

What side effects should you know about before starting the slimming injection?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion, and burping. These tend to be at their peak in the first few days after starting or stepping up a dose, and for most people they ease within one to two weeks. Eating smaller portions, avoiding fatty or very rich foods, and staying well hydrated all help the adjustment period.

Fatigue, headache, dizziness, and injection-site reactions (mild redness or itching at the injection point) are also reported. These are generally short-lived. Full side effect detail, including less common reactions, is on our Mounjaro side effects page.

One important safety note: in January 2026 the MHRA issued a Drug Safety Update reminding patients and clinicians that acute pancreatitis, though infrequent, is a known risk with GLP-1 medicines. Seek urgent medical help for severe stomach pain that radiates to the back, with or without vomiting. Any suspected side effect can be reported at Yellow Card, the MHRA's reporting system. If you are uncertain whether a symptom is related to treatment, contact your prescriber rather than waiting.

Thinking about cost alongside safety? The cost context page explains what legitimate private pricing covers and why clinical oversight is built into every prescription.